Tiziana Monteverde
Overview
Explore the profile of Tiziana Monteverde including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
354
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ismail M, Davies G, Sproat G, Monteverde T, Tart J, Acebron-Garcia-de-Eulate M, et al.
SLAS Discov
. 2024 Nov;
29(8):100197.
PMID: 39613028
The NanoBiT Biochemical Assay (NBBA) was designed as a biochemical format of the NanoBiT cellular assay, aiming to screen weak protein-protein interactions (PPIs) in mammalian cell lysates. Here we present...
2.
Farahmand P, Gyuraszova K, Rooney C, Raffo-Iraolagoitia X, Jayasekera G, Hedley A, et al.
Front Toxicol
. 2023 Jul;
5:1200650.
PMID: 37441092
Asbestos-driven inflammation contributes to malignant pleural mesothelioma beyond the acquisition of rate-limiting mutations. Genetically modified conditional allelic mice that were previously shown to develop mesothelioma in the absence of exposure...
3.
Cimini B, Chandrasekaran S, Kost-Alimova M, Miller L, Goodale A, Fritchman B, et al.
Nat Protoc
. 2023 Jun;
18(7):1981-2013.
PMID: 37344608
In image-based profiling, software extracts thousands of morphological features of cells from multi-channel fluorescence microscopy images, yielding single-cell profiles that can be used for basic research and drug discovery. Powerful...
4.
Trapotsi M, Mouchet E, Williams G, Monteverde T, Juhani K, Turkki R, et al.
ACS Chem Biol
. 2022 Jul;
17(7):1733-1744.
PMID: 35793809
PROteolysis TArgeting Chimeras (PROTACs) use the ubiquitin-proteasome system to degrade a protein of interest for therapeutic benefit. Advances made in targeted protein degradation technology have been remarkable, with several molecules...
5.
Shi L, Magee P, Fassan M, Sahoo S, Leong H, Lee D, et al.
Nat Commun
. 2021 Apr;
12(1):2038.
PMID: 33795683
Wild-type KRAS (KRAS) amplification has been shown to be a secondary means of KRAS activation in cancer and associated with poor survival. Nevertheless, the precise role of KRAS overexpression in...
6.
Monteverde T, Sahoo S, La Montagna M, Magee P, Shi L, Lee D, et al.
Cancer Res
. 2021 Jan;
81(7):1719-1731.
PMID: 33472893
Chromosomal instability (CIN) is a driver of clonal diversification and intratumor heterogeneity, providing genetic diversity that contributes to tumor progression. It is estimated that approximately 80% of solid cancers, including...
7.
Muthalagu N, Monteverde T, Raffo-Iraolagoitia X, Wiesheu R, Whyte D, Hedley A, et al.
Cancer Discov
. 2020 Mar;
10(6):872-887.
PMID: 32200350
MYC is implicated in the development and progression of pancreatic cancer, yet the precise level of MYC deregulation required to contribute to tumor development has been difficult to define. We...
8.
Neidler S, Kruspig B, Hewit K, Monteverde T, Gyuraszova K, Braun A, et al.
Cancers (Basel)
. 2019 Apr;
11(5).
PMID: 31032816
Inducible genetically defined mouse models of cancer uniquely facilitate the investigation of early events in cancer progression, however, there are valid concerns about the ability of such models to faithfully...
9.
Kruspig B, Monteverde T, Neidler S, Hock A, Kerr E, Nixon C, et al.
Sci Transl Med
. 2018 Jun;
10(446).
PMID: 29925636
KRAS is the most frequently mutated driver oncogene in human adenocarcinoma of the lung. There are presently no clinically proven strategies for treatment of KRAS-driven lung cancer. Activating mutations in...
10.
Port J, Muthalagu N, Raja M, Ceteci F, Monteverde T, Kruspig B, et al.
Cancer Discov
. 2018 Mar;
8(5):632-647.
PMID: 29500295
Exploiting oxidative stress has recently emerged as a plausible strategy for treatment of human cancer, and antioxidant defenses are implicated in resistance to chemotherapy and radiotherapy. Targeted suppression of antioxidant...